Close

Adenocarcinomas

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Overview

Adenocarcinoma is a type of cancer which occurs in several places of the body. It originates in glandular (secretory) cells that produce substances such as mucus, digestive juices, or other fluids, which can be found in several tissues throughout the body. Thus, adenocarcinomas can be diagnosed in many different organs, including the lungs, colon, pancreas, cervix and esophagus. It is the most common cancer form of breast, pancreas, lung, prostate, and colon.

Sign and symptom

Symptoms mentioned in various sources for adenocarcinoma include bleeding, pain, discomfort and lump. Other signs and symptoms of adenocarcinoma depend on the locations of the lesions in body and the development condition. For lung adenocarcinoma, the symptom can be a persistent cough and/or coughing up blood in progressed condition. For colorectal adenocarcinoma, the most common symptoms include blood in the stool, diarrhea, inexplicable weight loss, constipation, or abnormal bowel habits, vomiting, lack of appetite and cramping.

Loading...
Products
Global Services
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.